Table 2.
Parameter estimates of the models describing the milk production and the distribution of chemotherapy to breast milk
| Parameter | Patient 1 (RSE) | Patient 2 (RSE) | Patient 3 (RSE) | |
|---|---|---|---|---|
| Milk production | ||||
| Steady-state milk production | SSMP | 5.89 mL/h (0%) | 0 mL/h* (–) | 10.5 mL/h (0.01%) |
| Maximal breast capacity | MBC | 170 mL (0.01%) | 357 mL (0.01%) | 170 mL (0.03%) |
| Change in milk production | CMP | 41.5 mL/h (0.05%) | 60.6 mL/h (0.02%) | 20.5 mL/h (0.05%) |
| Change in milk production rate constant | CMPR | 0.0032 1/h (2.6%) | 0.0017 1/h (3.3%) | 0.0163 1/h (0.46%) |
| Residual unexplained variability additive error | – | 1020 mL (7%) | ||
| Cyclophosphamide | ||||
| Intercompartmental distribution | Q | 814 L/h (1%) | – | |
| Residual unexplained variability proportional error | – | 160.6% (85%) | – | |
| Doxorubicin | ||||
| Intercompartmental distribution | Q | 618 L/h (18%) | – | |
| Maximal transport rate | VMTR | 290 µg/h (5%) | – | |
| Michealis–Menten constant | KMTR | 0.013 µg/L (35%) | – | |
| Milk volume of distribution ratio | Vratio | 7.26× (8%) | – | |
| Residual unexplained variability proportional error | – | 24.7% (12%) | – | |
| Paclitaxel | ||||
| Intercompartmental distribution | Q | 2.06 L/h (2%) | – | – |
| Maximal transport rate | VMTR | 1.2 µg/h (6%) | – | – |
| Michealis–Menten constant | KMTR | 0.012 µg/L (35%) | – | – |
| Residual unexplained variability proportional error | – | 23.7% (1%) | – | – |
Estimates for the milk production were estimated for each patient separately, and other parameters were the same for each patients, if applicable
RSE relative standard error
*Steady-state milk production in patient 2 was not reached due to the absence of observations in the steady-state phase resulting in boundary errors near zero and was therefore fixed to zero. Estimates are only required for describing the milk production in each patient and are not used for simulations